Defects in the mitochondrial respiratory chain (RC) underlie a spectrum of human conditions, ranging from devastating inborn errors of metabolism to aging. We performed a genome-wide, Cas9-mediated screen to identify factors that are protective during RC inhibition. Our results highlight the hypoxia response, an endogenous program evolved to adapt to limiting oxygen availability. Genetic or small molecule activation of the hypoxia response is protective against mitochondrial toxicity in cultured cells and zebrafish models. Chronic hypoxia leads to a marked improvement in survival, body weight, body temperature, behavior, neuropathology and disease biomarkers in a genetic mouse model of Leigh syndrome, the most common pediatric manifestation of mitochondrial disease. Further preclinical studies are required to assess whether hypoxic exposure can be developed into a safe and effective treatment for human diseases associated with mitochondrial dysfunction.

Genetic mapping of mutations in model systems has facilitated the identification of genes contributing to fundamental biological processes including human diseases. However, this approach has historically required the prior characterization of informative markers. Here we report a fast and cost-effective method for genetic mapping using next-generation sequencing that combines single nucleotide polymorphism discovery, mutation localization, and potential identification of causal sequence variants. In contrast to prior approaches, we have developed a hidden Markov model to narrowly define the mutation area by inferring recombination breakpoints of chromosomes in the mutant pool. In addition, we created an interactive online software resource to facilitate automated analysis of sequencing data and demonstrate its utility in the zebrafish and mouse models. Our novel methodology and online tools will make next-generation sequencing an easily applicable resource for mutation mapping in all model systems.[Supplemental material is available for this article.]There can be little argument that genetic mapping has made a substantial contribution to our understanding of biology. For many years these studies used phenotypically defined markers, such as those used by Morgan in Drosophila and Haldane in mice (Morgan 1911;Haldane et al. 1915). The modern era of genetic analysis was heralded by the recognition that variation in genomic DNA sequence itself could be used as a facile assay for mapping (Botstein et al. 1980). This was initially accomplished using analysis of restriction fragmentlength polymorphisms, which were later replaced by microsatellites and subsequently by single nucleotide polymorphisms (SNPs). Despite the remarkable technological advances, these approaches hold in common with those of Morgan and Haldane the utilization of prespecified markers. Next-generation sequencing (NGS) technology enables simultaneous discovery of very dense sets of informative markers and actual gene mapping in the same experiment. Here, we present a strategy and computational tools to map genes in model organisms using sequencing of pooled samples. The approach can be applied to any model organism with a characterized genome and also to both spontaneous and induced mutants. We demonstrate the utility of the strategy and efficiency of the computational approach by mapping spontaneous and ethylnitrosourea (ENU)-induced developmental mutants in zebrafish and mouse.Large-scale forward mutagenesis screens in zebrafish have been used with success to investigate fundamental developmental processes. While the recent completion of the zebrafish genome has greatly aided in the identification of genes, mapping analyses continue to rely on the use of traditional microsatellite markers. However, the utilization of SNPs for mapping of zebrafish mutants was proposed almost a decade ago (Stickney et al. 2002), large numbers of SNPs have been identified (Guryev et al. 2006;Bradley et al. 2007), and the application of NGS for SNP discovery and mutat...

Endocannabinoid (EC) signaling mediates psychotropic effects and regulates appetite. By contrast, potential roles in organ development and embryonic energy consumption remain unknown. Here, we demonstrate that genetic or chemical inhibition of cannabinoid receptor (Cnr) activity disrupts liver development and metabolic function in zebrafish (Danio rerio), impacting hepatic differentiation, but not endodermal specification: loss of cannabinoid receptor 1 (cnr1) and cnr2 activity leads to smaller livers with fewer hepatocytes, reduced liver-specific gene expression and proliferation. Functional assays reveal abnormal biliary anatomy and lipid handling. Adult cnr2 mutants are susceptible to hepatic steatosis. Metabolomic analysis reveals reduced methionine content in Cnr mutants. Methionine supplementation rescues developmental and metabolic defects in Cnr mutant livers, suggesting a causal relationship between EC signaling, methionine deficiency and impaired liver development. The effect of Cnr on methionine metabolism is regulated by sterol regulatory element-binding transcription factors (Srebfs), as their overexpression rescues Cnr mutant liver phenotypes in a methioninedependent manner. Our work describes a novel developmental role for EC signaling, whereby Cnr-mediated regulation of Srebfs and methionine metabolism impacts liver development and function.